Poor
Partially Aligned
Patient Risk:
Medium
Summary
Only some biomedical claims align with the provided label excerpts (CTLA-4 targeting; mechanism; melanoma indication; RCC indication). Several other claims provided by the AI are not supported by the supplied label text (pricing, patient assistance programs, and eligibility/discount specifics).
Category Scores
Accurate Statements
Yervoy (ipilimumab) is a monoclonal antibody that targets CTLA-4.
11 DESCRIPTION; 12.1 Mechanism of Action: ipilimumab is a CTLA-4-blocking antibody; binds to CTLA-4 and blocks interaction with ligands.
By blocking CTLA-4, Yervoy allows T-cells to attack cancer cells more effectively.
12.1 Mechanism of Action: blockade augments T-cell activation and proliferation, including tumor infiltrating T-effector cells; increases general T-cell responsiveness and anti-tumor immune response.
Yervoy is FDA-approved for the treatment of melanoma.
1.1 Unresectable or Metastatic Melanoma: indicated for unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.
Unsupported Statements
Yervoy is FDA-approved for the treatment of kidney cancer.
The supplied label excerpt specifies advanced renal cell carcinoma (RCC) in combination with nivolumab (first-line intermediate or poor risk). 'Kidney cancer' is broader than the provided label language; not directly supported as stated.
The average wholesale price of Yervoy is around $120,000 per year.
Not supported by the supplied prescribing information excerpts (no pricing/wholesale price information provided).
Bristol-Myers Squibb offers a patient assistance program (PAP) that provides discounts on Yervoy for eligible patients.
No patient assistance program or discount information is included in the supplied label excerpts.
Bristol-Myers Squibb's Yervoy PAP can provide up to 100% off the cost of Yervoy for patients who meet certain eligibility criteria.
No PAP, discount, or 100% off cost information is included in the supplied label excerpts.
The Cancer Financial Assistance Coalition offers financial assistance to patients taking Yervoy.
No non-profit financial assistance program information is included in the supplied label excerpts.
Patients may be eligible for up to $10,000 in financial assistance per year from the Cancer Financial Assistance Coalition while taking Yervoy.
No financial assistance amount or eligibility information is included in the supplied label excerpts.
Many pharmaceutical companies, including Bristol-Myers Squibb (the manufacturer of Yervoy), offer patient assistance programs (PAPs) that provide discounts on medications for eligible patients.
No general statements about PAPs or manufacturer-specific assistance programs are included in the supplied label excerpts.
Some manufacturers offer discounts on medications including Yervoy, as a percentage off the list price or as a fixed amount off the cost of the medication.
No manufacturer discount structures (percentage off list price/fixed amount) are included in the supplied label excerpts.
Government programs such as Medicaid and the Veterans Administration may offer discounts on Yervoy for eligible patients.
No information about Medicaid/VA discounts is included in the supplied label excerpts.
Non-profit organizations such as the Cancer Financial Assistance Coalition may offer financial assistance to patients taking Yervoy.
No non-profit assistance program information is included in the supplied label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The AI did not provide dosage and administration details or safety elements (contraindications, boxed warnings, warnings/precautions, monitoring, adverse reactions) that would be needed for a full label alignment check.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While the biomedical mechanism and melanoma indication are supported by the provided label excerpts, multiple unsupported financial/PAP/discount claims could mislead patients about access cost and assistance availability; these are not verifiable against the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported claims regarding pricing and patient assistance/discount programs are not present in the supplied prescribing information excerpts.
Suggested Improvement
Limit statements to label-supported content (e.g., CTLA-4 mechanism and the specific listed indications such as unresectable/metastatic melanoma and advanced renal cell carcinoma as specified), and remove or qualify any pricing or assistance-program claims unless supported by the provided FDA-approved label text.